Jardiance vs Trulicity
Side-by-side cost comparison based on Medicare Part D data
Jardiance
Empagliflozin
Manufactured by Boehringer Ingelheim
Trulicity
Dulaglutide
Manufactured by Eli Lilly
Jardiance costs 56% less per claim than Trulicity ($210.00 vs $473.00). A generic version of Jardiance is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Jardiance | Trulicity |
|---|---|---|
| Avg Cost Per Claim | $210.00 | $473.00 |
| Total Medicare Spending | $3.9B | $4.2B |
| Total Beneficiaries | 2,150,000 | 985,000 |
| Total Claims | 18,760,000 | 8,920,000 |
| Annual Cost/Patient | $1,835.00 | $4,279.00 |
| Year-over-Year Change | +22.7% | -4.8% |
| Generic Available | Yes | No |
| Patent Expiration | May 23, 2025 | Sep 18, 2027 |
| Manufacturer | Boehringer Ingelheim | Eli Lilly |
| Condition | Diabetes | Diabetes |
| Generic Name | Empagliflozin | Dulaglutide |
Jardiance vs Trulicity: What the Data Shows
Jardiance (Empagliflozin) and Trulicity (Dulaglutide) are both used to treat diabetes. Based on Medicare Part D data, Jardiance costs $210.00 per claim, which is 56% less than Trulicity at $473.00 per claim.
Medicare spent $3.9B on Jardiance and $4.2B on Trulicity. In terms of patient reach, Jardiance serves more beneficiaries (2,150,000 vs 985,000).
Year-over-year spending changed +22.7% for Jardiance and -4.8% for Trulicity. Jardiance saw significant spending growth, suggesting increased utilization or price increases.
Jardiance has a generic available, while Trulicity remains brand-only until its patent expires Sep 18, 2027.
Frequently Asked Questions
Jardiance is cheaper at $210.00 per claim, compared to $473.00 for Trulicity. That makes Jardiance about 56% less expensive per claim based on Medicare Part D data.
Yes, both Jardiance and Trulicity are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Jardiance has a generic version (Empagliflozin) available, which is typically much cheaper. Trulicity is currently brand-only, with patent expiring Sep 18, 2027.
Medicare Part D spent $3.9B on Jardiance covering 2,150,000 beneficiaries, and $4.2B on Trulicity covering 985,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.